GoAI
Get started
IRadimed Corporation logo

IRadimed Corporation

IRMD

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$87.85

+$1.17 · +1.35%

Aug 21, 4:00 PM ET

IRMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

52

Neutral

Sentiment

39

Bearish

Risk resilience

71

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Roger E. Susi
Listed since
Jul 16, 2014
Employees
166

Market position

Day range

Current $87.85

52-week range

Current $87.85

Open
$86.83
Previous close
$86.68
Volume
76.18K
0.58× average
Average volume
131.73K
Average daily volume
Market cap
1.12B USD
Beta
0.91
Market reference 1
50-day average
$93.3195
-5.86% below average
200-day average
$94.4157
-6.95% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.19B USD
P/E (TTM)
48.27×
P/B (TTM)
11.04×
P/S (TTM)
13.01×
EV / EBITDA
38.59×
Earnings yield
1.82%
Free cash flow yield
1.39%
Dividend yield
1.45%

Profitability & efficiency

Gross margin
75.86%
Operating margin
31.92%
Net margin
26.70%
Return on equity
23.76%
Return on assets
20.67%
Return on invested capital
21.02%

Financial health

Debt / equity
0×
Current ratio
7.98×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%61%39%17%Gross margin, FY2021: 76.65%Gross margin, FY2022: 77.45%Gross margin, FY2023: 76.50%Gross margin, FY2024: 76.94%Gross margin, FY2025: 76.75%Operating margin, FY2021: 23.48%Operating margin, FY2022: 29.32%Operating margin, FY2023: 30.56%Operating margin, FY2024: 29.99%Operating margin, FY2025: 31.20%Net margin, FY2021: 22.30%Net margin, FY2022: 24.07%Net margin, FY2023: 26.22%Net margin, FY2024: 26.26%Net margin, FY2025: 26.82%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 76.65%. Gross margin FY2022 77.45%. Gross margin FY2023 76.50%. Gross margin FY2024 76.94%. Gross margin FY2025 76.75%. Operating margin FY2021 23.48%. Operating margin FY2022 29.32%. Operating margin FY2023 30.56%. Operating margin FY2024 29.99%. Operating margin FY2025 31.20%. Net margin FY2021 22.30%. Net margin FY2022 24.07%. Net margin FY2023 26.22%. Net margin FY2024 26.26%. Net margin FY2025 26.82%.

Income trends

Revenue

83.81M USD+14.43%

Operating income

26.15M USD+19.04%

Net income

22.48M USD+16.88%
Income trends across reported periods91.26M USD61.47M USD31.67M USD1.88M USDRevenue, FY2021: 41.81M USDRevenue, FY2022: 53.3M USDRevenue, FY2023: 65.56M USDRevenue, FY2024: 73.24M USDRevenue, FY2025: 83.81M USDOperating income, FY2021: 9.82M USDOperating income, FY2022: 15.63M USDOperating income, FY2023: 20.04M USDOperating income, FY2024: 21.96M USDOperating income, FY2025: 26.15M USDNet income, FY2021: 9.33M USDNet income, FY2022: 12.83M USDNet income, FY2023: 17.19M USDNet income, FY2024: 19.23M USDNet income, FY2025: 22.48M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 41.81M USD. Revenue FY2022 53.3M USD. Revenue FY2023 65.56M USD. Revenue FY2024 73.24M USD. Revenue FY2025 83.81M USD. Operating income FY2021 9.82M USD. Operating income FY2022 15.63M USD. Operating income FY2023 20.04M USD. Operating income FY2024 21.96M USD. Operating income FY2025 26.15M USD. Net income FY2021 9.33M USD. Net income FY2022 12.83M USD. Net income FY2023 17.19M USD. Net income FY2024 19.23M USD. Net income FY2025 22.48M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue83.81M USD73.24M USD65.56M USD53.3M USD41.81M USD
Cost of goods sold19.49M USD16.89M USD15.4M USD12.02M USD9.76M USD
Gross profit64.32M USD56.35M USD50.16M USD41.28M USD32.05M USD
Research and development2.98M USD2.83M USD2.86M USD2.28M USD1.91M USD
Selling, general, and administrative35.2M USD31.55M USD27.26M USD23.38M USD20.33M USD
Operating expenses38.18M USD34.39M USD30.12M USD25.65M USD22.23M USD
Interest income—2.19M USD1.86M USD581.85K USD34.81K USD
Depreciation and amortization2.38M USD817.66K USD765.18K USD670.67K USD1.41M USD
Operating income26.15M USD21.96M USD20.04M USD15.63M USD9.82M USD
Net income22.48M USD19.23M USD17.19M USD12.83M USD9.33M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+4.82%
11 comparable reports
Latest EPS result
0.46
Estimate 0.44 · Beat by 4.55%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.580.510.450.38Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 0.44, estimate 0.45, surprise -2.22%, Miss. Q2 2025, reported May 5, 2025: actual 0.42, estimate 0.43, surprise -2.33%, Miss. Q3 2025, reported Aug 1, 2025: actual 0.49, estimate 0.45, surprise +8.89%, Beat. Q4 2025, reported Nov 3, 2025: actual 0.47, estimate 0.48, surprise -2.08%, Miss. Q1 2026, reported Feb 10, 2026: actual 0.54, estimate 0.49, surprise +10.20%, Beat. Q2 2026, reported May 1, 2026: actual 0.49, estimate 0.45, surprise +8.89%, Beat. Q3 2026, reported Jul 31, 2026: actual 0.46, estimate 0.44, surprise +4.55%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 0.52, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates24.13M22.18M20.22M18.27MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 19.39M USD, estimate 19.2M USD, surprise +0.99%, Beat. Q2 2025, reported May 5, 2025: actual 19.51M USD, estimate 19.33M USD, surprise +0.92%, Beat. Q3 2025, reported Aug 1, 2025: actual 20.41M USD, estimate 20.5M USD, surprise -0.43%, Miss. Q4 2025, reported Nov 3, 2025: actual 21.2M USD, estimate 21.6M USD, surprise -1.83%, Miss. Q1 2026, reported Feb 10, 2026: actual 22.69M USD, estimate 21.6M USD, surprise +5.06%, Beat. Q2 2026, reported May 1, 2026: actual 21.98M USD, estimate 21.32M USD, surprise +3.12%, Beat. Q3 2026, reported Jul 31, 2026: actual 20.47M USD, estimate 20.35M USD, surprise +0.57%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 23.2M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$100

13.83% upside
Past 12 months12-month forecastHigh $120Average $100Low $60.00

IRMD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IRMD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
24.02M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
18.51M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
8.38M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
6.91M
Weight
0.05%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
4.33M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
3.85M
Weight
0.05%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
3.69M
Weight
0.02%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
First Trust Small Cap Growth AlphaDEX Fund logoFirst Trust Small Cap Growth AlphaDEX FundFYC
Market value
3.39M
Weight
0.24%
AUM
1.42B USD
Expense ratio
0.70%
Price / 1D
$122+0.71%

Continue in GoAI

Research IRMD

research.disclaimer